- •Recent guideline changes dramatically increase eligibility for germline testing among patients with somatic mutations in moderate risk breast and ovarian cancer susceptibility genes.
- •Traditional germline testing guidelines based on personal and family history do not adequately capture hereditary cancer syndromes associated with moderate risk breast and ovarian cancer genes among a cohort of advanced cancer patients.
- •Rates of germline confirmation are ∼40% or higher in patients with TGP-identified mutations in ATM, CHEK2, and PALB2.
- •In the context of limited healthcare resources, more study is needed to determine which TGP-identified mutations should be prioritized for referral to cancer genetics to maximize hereditary cancer syndrome diagnoses and limit the burden on cancer genetics clinics.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Identification and confirmation of potentially actionable germline mutations in tumor-only genomic sequencing.JCO Precis Oncol. 2019; : 1-11https://doi.org/10.1200/po.19.00076
- Yield and utility of germline testing following tumor sequencing in patients with cancer.JAMA Netw Open. 2020; 3e2019452https://doi.org/10.1001/jamanetworkopen.2020.19452
- Germline variants in targeted tumor sequencing using matched normal DNA.JAMA Oncol. 2016; 2: 104-111https://doi.org/10.1001/jamaoncol.2015.5208
- Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.JAMA - J Am Med Assoc. 2017; 318: 825-835https://doi.org/10.1001/jama.2017.11137
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.Annals Oncol. 2016; 27: 795-800https://doi.org/10.1093/annonc/mdw018
- Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings.Clin Cancer Res. 2016; 22: 4087-4094https://doi.org/10.1158/1078-0432.CCR-16-0015
- Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.JNCCN. 2021; 19: 77-102https://doi.org/10.6004/jnccn.2021.0001
- American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility.J Clin Oncol. 2015; 33: 3660-3667https://doi.org/10.1200/JCO.2015.63.0996
- Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).Genet Med. 2020; 22: 1142-1148https://doi.org/10.1038/s41436-020-0783-8
- Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.J Mol Diagn. 2017; 19: 4-23https://doi.org/10.1016/j.jmoldx.2016.10.002
- Somatic tumor testing implications for Lynch syndrome germline genetic testing.Cancer Genet. Jun 2022; 264-265: 16-22https://doi.org/10.1016/j.cancergen.2022.02.010
- Amin MB Edge S Green F AJCC cancer staging manual. 8th ed. Springer International Publishing, 2017
- Genetic/familial high-risk assessment: colorectal, Version 1.2021; 2021.J Natl Compr Canc Netw. 2021 Oct 15; 19: 1122-1132https://doi.org/10.1164/jnccn.2021.0048
- Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.J. Clin Oncol. 2019; 37: s1580https://doi.org/10.1200/JCO.2019.37.15_suppl.1580
- When should tumor genomic profiling prompt consideration of germline testing.J Oncol Pract. 2019; 15: 465-473https://doi.org/10.1200/JOP.19.00201
- Tumor-based genetic testing and familial cancer risk.Cold Spring Harbor Perspect Med. 2020; 10a036590https://doi.org/10.1101/cshperspect.a036590
- Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline.J Clin Oncol. 2020; 38: 1222-1245https://doi.org/10.1200/JCO.19
- Consensus guidelines on genetic` testing for hereditary breast cancer from the American Society of Breast Surgeons.Annals Surgical Oncol. 2019; 26: 3025-3031https://doi.org/10.1245/s10434-019-07549-8
- Germline testing for patients with BRCA1/2 mutations on somatic tumor testing.JNCI Cancer Spectrum. 2020; 4https://doi.org/10.1093/jncics/pkz095
- A clinical approach to detecting germline pathogenic variants from tumor-only sequencing.JNCI Cancer Spectrum. 2020; 4https://doi.org/10.1093/JNCICS/PKAA019